DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Gilotrif (Afatinib) - Summary

 
 



GILOTRIF SUMMARY

GILOTRIF tablets contain afatinib, a tyrosine kinase inhibitor which is a 4-anilinoquinazoline.

GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test [see Clinical Studies ].

Limitation of Use: Safety and efficacy of GILOTRIF have not been established in patients whose tumors have other EGFR mutations [see Clinical Studies].


See all Gilotrif indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Gilotrif (Afatinib)

Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. [2014]
BACKGROUND: Over 50% of patients with head and neck squamous cell carcinoma (HNSCC) present with locoregionally advanced disease. Those at intermediate-to-high risk of recurrence after definitive therapy exhibit advanced disease based on tumour size or lymph node involvement, non-oropharynx primary sites, human papillomavirus (HPV)-negative oropharyngeal cancer, or HPV-positive oropharynx cancer with smoking history (>10-pack-years)...

Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). [2013]
in a double-blind, randomized, phase IIb/III trial (LUX-Lung 1)... CONCLUSION: In the LUX-Lung 1 trial, the addition of afatinib to BSC

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. [2012]
tyrosine-kinase inhibitors... INTERPRETATION: Although we recorded no benefit in terms of overall survival with

A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. [2014]
mutations was also evaluated... CONCLUSIONS: The efficacy of afatinib was inferior to cetuximab in patients with

Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib. [2014]
evaluated in two randomised trials... CONCLUSIONS: Tumour progression in patients with NSCLC was associated with

more studies >>

Clinical Trials Related to Gilotrif (Afatinib)

Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck [Recruiting]
The purpose of this study is to evaluate the efficacy and safety of Afatinib in maintenance therapy after post-operative radiochemotherapy (66 Gy and Cisplatin at the dose of 100mg/m2 every 3 weeks)in squamous cell carcinoma of the head and neck.

The Safety and Efficacy Study of Afatinib (CT) Compared With Afatinib (GIOTRIF) in Patients With Solid Tumors (Including Mutations Identified EGFR) [Active, not recruiting]

Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients [Recruiting]

Safety Study of Afatinib for Brain Cancer [Not yet recruiting]
The purpose of this study is to try to determine the maximum safe dose of afatinib that can be administered to people with brain cancer. Other purposes of this study are to:

- find out what effects (good and bad) afatinib has;

- see how much drug gets into the body by collecting blood and cerebrospinal fluid for

use in pharmacokinetic (PK) studies;

- learn more about how afatinib might affect the growth of cancer cells;

- look at biomarkers (biochemical features that can be used to measure the progress of

disease or the effects of a drug).

LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib [Completed]
The objective of the Phase I step is to estimate the MTD at a dose level up to 50 mg/day (i. e., overseas recommended Phase II dose) in patients with advanced NSCLC and to determine the recommended dose for the Phase II step. The objective of the Phase II step is to estimate the efficacy of BIBW 2992 monotherapy in patients with first generation EGFR-TKI-resistant advanced NSCLC at the recommended dose determined in the Phase I step.

more trials >>


Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017